Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Epacadostat in Advanced NSCLC and Urothelial Carcinoma
NCT02298153Phase 1Terminated
- Sponsor
- Incyte
- Start
- Jan 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of epacadostat in non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC) (6 arms), sponsored by Incyte. Primary endpoints: Incidence of adverse events up to 8 months and Incidence of dose-limiting toxicities at 21 days. Started Jan 2015; status: terminated.
02
Drugs
epacadostat
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02298153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298153.